Vanda Pharmaceuticals GAAP EPS of -$0.50 beats by $0.10, revenue of $50.04M beats by $4.91M

Stock Information for Vanda Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results
Vanda Announces Bysanti(TM) NDA Filing; FDA Decision Expected in Early 2026
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.